Search results
Sanofi Expected to Post Q2 2024 Earnings of $0.90 Per Share (NASDAQ:SNY)
ETF DAILY NEWS· 1 day agoSanofi (NASDAQ:SNY – Free Report) – Equities research analysts at Leerink Partnrs cut their Q2 2024 EPS estimates for shares of Sanofi in a report released ...
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoSanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS,...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 2 hours agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth over...
Sanofi ADR (NASDAQ: SNY) Is Up 0.29% – Is It Capable Of A Rally? – Stocks Register
Stocks Register· 1 day agoSanofi ADR (NASDAQ:SNY) traded at $49.23 at close of the session on Tuesday, April 30, made an upward move of 0.29% on its previous day’s price. Looking at the stock we see ...
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks via Yahoo Finance· 7 days agoSanofi SNY reported first-quarter 2024 adjusted earnings of 96 cents per American depositary share,...
RSV vaccine boosts Monroe County's Sanofi Pasteur
WFMZ Eastern Pennsylvania and Western New Jersey· 7 days agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in first-quarter revenue on Thursday, as sales of vaccines and the...
Sanofi reports 1Q revenue increase, as sales of vaccines, Dupixent rise
WFMZ Eastern Pennsylvania and Western New Jersey· 7 days agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in...
AstraZeneca, Sanofi Bolt Higher On Quarterly Beats, But Bristol Myers Dives
Investor's Business Daily· 7 days agoThe Cambridge U.K.-based drugmaker reported almost $5.11 billion in sales of its cancer drugs. Sales...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant...
Benzinga· 4 hours agoBeyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease
Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy By Investing.com
Investing.com· 7 days agoSanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
